Download the free whitepaper: Unravelling the complexities of genomics-driven drug discovery

Genomics-driven drug discovery holds immense promise in developing targeted therapies by leveraging genetic and biomarker information to understand the root causes of diseases. However, the field faces significant hurdles.

In this whitepaper, we examine the obstacles of limited recontactability, scarcity of multi-omics data sets, lack of diversity in data, and the challenge of scaling research for rare diseases. By addressing these challenges and proposing strategies to address them, this whitepaper aims to chart a path by which we can harness the full potential of genomics-driven drug discovery.

 

whitepaper image
download icon

Download report

Diagnostics, data, and site readiness: What world-leading CGT programs get right

Integrated diagnostics, longitudinal data, and site readiness as foundational CGT infrastructure

Cell and gene therapy programs increasingly succeed or fail based on execution rather than scientific feasibility. Delays in diagnosis, fragmented data infrastructure, and underprepared clinical sites can derail programs long before efficacy is in question.

This report examines how leading CGT sponsors approach diagnostics, longitudinal data, and site readiness as shared infrastructure, and why addressing these elements early is critical for predictable clinical execution.

In this report, you'll learn:
✅ Why late patient identification remains a major constraint in CGT trials
✅ How leading programs design data foundations that support long-term follow-up
✅ What early site readiness looks like in successful CGT development

Who this report is for:
➡️ Cell and gene therapy clinical development leaders
➡️ Rare disease and translational medicine teams
➡️ Clinical operations and trial delivery teams

Download now to learn more.

ddgroup